41. Giant cell arteritis Clinical trials / Disease details

Clinical trials : 131 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 125

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05380453 (ClinicalTrials.gov)	September 21, 2022	22/2/2022	Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission	A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Efficacy and Safety of Subcutaneously Administered Secukinumab in Patients With New-onset of Giant Cell Arteritis (GCA) Who Are in Clinical Remission and Eligible for Treatment With Glucocorticoid-monotherapy	Giant Cell Arteritis	Biological: Secukinumab 300 mg, s.c.;Drug: Placebo to match Secukinumab, s.c.	Novartis Pharmaceuticals	NULL	Recruiting	50 Years	N/A	All	146	Phase 3	Germany
2	NCT03765788 (ClinicalTrials.gov)	January 30, 2019	3/12/2018	A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis	A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab (AIN457) in Patients With Giant Cell Arteritis (TitAIN)	Giant Cell Arteritis	Drug: Secukinumab 300 mg, s.c.;Drug: Prednisolone;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	50 Years	N/A	All	52	Phase 2	Germany